Evidence map›Paper›PMID 40956876›Full record

ArticleScience signaling2025

Wild-type RAS signaling is an essential therapeutic target in

Nancy E Sealover, Bridget A Finniff, Jacob M Hughes, Erin Sheffels, Hyun Lee, Joseph P LaMorte, Vainavi Gambhir, Zaria Beckley, Amanda Linke, Matthew D Wilkerson and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science signaling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASbioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Nancy E SealoverDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0000-0002-6463-5836
Bridget A FinniffDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Jacob M HughesDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0009-0007-6686-5014
Erin SheffelsDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0000-0001-8356-6517
Hyun LeeDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Joseph P LaMorteDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0009-0004-3160-0938
Vainavi GambhirDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0009-0001-5359-1073
Zaria BeckleyDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Amanda LinkeDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0000-0001-5719-9696
Matthew D WilkersonDepartment of Anatomy, Physiology, and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0000-0003-2727-0230
Marielle E YoheLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21701, USA.ORCID 0000-0001-5356-9426
Robert L KortumDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID 0000-0002-1634-4882

Funding

Isoform-specific signaling as a determinant of RAS-driven oncogenesisR01CA255232 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI Robert Kortum · 2022 to 2026
$1.7M
NCI NIH HHS R01 CA255232
6 · The paper itself

Abstract

Mutated RAS proteins activate downstream effector pathways (RAF-MEK-ERK and PI3K-AKT) to drive oncogenic transformation and progression. Because RAS family members differentially engage these pathways, combined inhibition of both pathways is required to effectively treat

Indexed as

Neoplasmsras ProteinsSignal TransductionAnimalsAntineoplastic AgentsCell Line, TumorFibroblastsGene Knockout TechniquesHumansMAP Kinase Signaling SystemMicePhosphatidylinositol 3-KinasesQuinolonesAntineoplastic AgentsPhosphatidylinositol 3-KinasesQuinolonesras Proteinstipifarnib

Identifiers

PMID40956876
PMCPMC12983336

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.